Collaboration - April 7, 2026
Norwegian collaboration in radiopharmacy against cancer
Thor Medical has entered into a multiyear frame agreement with Node Pharma for the supply of radium-224 and lead-212 for preclinical use.
Acquisition - April 7, 2026
MSD to acquire Terns Pharmaceuticals
MSD and Terns Pharmaceuticals have entered into a definitive agreement under which MSD, through a subsidiary, will acquire Terns for an approximate equity value of USD 6.7 billion.
New Market - April 7, 2026
Immedica announces first marketing authorization approval in the MENA region
Immedica has announced that the Kuwait Ministry of Health (MOH) has granted Marketing Authorization (MA) approval for Ztalmy (ganaxolone) for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in Kuwait.
Biotech Business - April 7, 2026
Biosergen Pauses Development of BSG005
Against the backdrop of a continued challenging financing environment, the Board of Directors of Biosergen has resolved to pause the development of BSG005.
Acquisition - April 1, 2026
Eli Lilly and Company to acquire Centessa Pharmaceuticals
Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to address the neurobiological system critical to the sleep-wake cycle to treat excessive daytime sleepiness and disorders of impaired wakefulness.
Acquisition - April 1, 2026
Biogen to acquire Apellis Pharmaceuticals
The two companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for USD 41.00 per share in cash at closing, or approximately USD 5.6 billion.
